Title

Cetuximab-related Hypersensitivity Reactions in Northeast Tennessee

Document Type

Presentation

Publication Date

3-1-2012

Description

Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lower reaction rates of 3%.

Location

Orlando, FL

This document is currently not available here.

Share

COinS